Using blood tests to improve lung cancer diagnosis and treatment
Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study
This study is testing if using blood tests to analyze tumor DNA can help doctors diagnose and treat advanced lung cancer more effectively for patients in the Southeast of the Netherlands.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Catharina Ziekenhuis Eindhoven Academic / other |
| Locations | 5 sites (Heerlen, Limburg and 4 other locations) |
| Trial ID | NCT06105177 on ClinicalTrials.gov |
What this trial studies
This study aims to implement a 'plasma first approach' by analyzing circulating tumor DNA (ctDNA) in patients suspected of having advanced stage lung cancer in the Southeast of the Netherlands. By integrating ctDNA analysis into routine diagnostic work-ups, the study seeks to provide more information about the tumor's molecular characteristics, reduce the need for tissue biopsies, and expedite therapeutic decision-making. The study will also develop decision support models to predict outcomes and improve patient management. It involves a multicenter, prospective cohort of 800 patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are suspected of having lung cancer.
Not a fit: Patients with another malignant tumor diagnosed within the past 5 years may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to faster and more accurate lung cancer diagnoses and personalized treatment plans for patients.
How similar studies have performed: Other studies have shown promise in using liquid biopsy techniques for cancer diagnosis, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 or above and suspected of having lung cancer Exclusion Criteria: * Presence of another malignant tumor, i.e. diagnosed with a tumor in the past 5 years
Where this trial is running
Heerlen, Limburg and 4 other locations
- Zuyderland Medical Center — Heerlen, Limburg, Netherlands (Not_yet_recruiting)
- Maastricht University Medical Center — Maastricht, Limburg, Netherlands (Not_yet_recruiting)
- Catharina Ziekenhuis Eindhoven — Eindhoven, North Brabant, Netherlands (Recruiting)
- St. Anna Ziekenhuis — Geldrop, North Brabant, Netherlands (Not_yet_recruiting)
- Máxima Medisch Centrum — Veldhoven, North Brabant, Netherlands (Not_yet_recruiting)
Study contacts
- Principal investigator: Volkher Scharnhorst, Prof.Dr. — Catharina Ziekenhuis Eindhoven
- Study coordinator: Hao Cao, MSc
- Email: hao.cao@catharinaziekenhuis.nl
- Phone: +31402398644
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.